Pular para o conteúdo principal
Ranking Invest

VSTM - Verastem, Inc.

Segmento: HealthcareVerastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Análise Ranking Invest

Valor de Mercado
$ 1.19 Bi
IVR
-0.36Índice proprietário de comparação relativa: -0,36.
IVR2
-0.41Leitura proprietária complementar: -41%.
MLL
-0.41Leitura proprietária complementar: -41%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 49.99 Mi

Dívida Líquida

-$ 136.35 Mi

L4T

-$ 202.70 Mi

MM4T

-289.71%

Indicadores Básicos

ROE

-405.51%

Índices de Previsibilidade

Receita Líquida

G1.54

Lucro

C0.28

Margem

F1.98

Índices de Tendência

Receita Líquida

C4.96

Lucro

F-6.96

Margem

E-2.00

Índices de Endividamento

DIV/PAT

-2.73

DIV/L4T

0.67

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.